- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07270562
Aterectomía Orbital para la Preparación de Lesiones en Pacientes con Isquemia Crónica de las Extremidades Amenazante (ORACLE)
Aterectomía Orbital para la Preparación de Lesiones en Pacientes con Isquemia Crónica de Miembros Amenazante
ORACLE is a Europe-wide study that will follow 250 people with critical limb-threatening ischemia (CLTI). It aims to see how well orbital atherectomy (OA) works in real-life practice. OA is a procedure that uses a tiny spinning tool to gently remove hard calcium from inside an artery, helping to open the vessel so other treatments-like balloons or stents-can work better. The study focuses on people who have heavily calcified arteries in the femoropopliteal or infrapopliteal areas of the leg.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Claire Poulet, PhD
- Número de teléfono: +41 79 385 16 78
- Correo electrónico: oracue@cirse.org
Copia de seguridad de contactos de estudio
- Nombre: Dhwani S. Korde, PhD
- Número de teléfono: +4367762942469
- Correo electrónico: oracue@cirse.org
Ubicaciones de estudio
-
-
-
Hull, Reino Unido, HU3 2JZ
- Reclutamiento
- Hull University Teaching Hospitals NHS Trust
-
Investigador principal:
- Raghu Lakshminarayan, Dr
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adult CLTI patients with femoropopliteal or infrapopliteal calcified lesions treated with OA using the Stealth 360 Peripheral OA System for vessel preparation prior to any adjunctive endovascular procedure.
Descripción
Inclusion Criteria:
- Rutherford classification category ≥4;
- Treatment of femoropopliteal or infrapopliteal calcified lesions with OA using the Stealth 360 peripheral OA System;
- Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
- Patients competent and willing to provide informed consent.
Exclusion Criteria:
- Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
- Inadequate inflow (>30% stenosis) following optimization;
- Insufficient direct outflow (less than 1 run-off vessel);
- Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
- Patients planned to receive an above ankle amputation of the target limb;
- Patients enrolled in RESCUE (ClinicalTrials.gov ID NCT07270575).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Adult CLTI patients with femoropopliteal or infrapopliteal calcified lesions
Eligible patients are those who will undergo OA prior to any adjunctive endovascular procedure |
The Stealth 360™ Peripheral Orbital Atherectomy System uses a diamond-coated, eccentrically mounted crown with bi-directional capabilities that treat a wide range of vessels, enabling single device treatment of multiple lesions and vessel sizes.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of lesions with ≤30% residual stenosis after completion of full planned procedure
Periodo de tiempo: Immediately after procedure completion
|
Defined as residual stenosis ≤30%, immediately after completion of full planned procedure (OA + any planned adjunctive intervention(s)). |
Immediately after procedure completion
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of lesions with ≤30% residual stenosis after any unplanned endovascular intervention(s)
Periodo de tiempo: Immediately after procedure completion
|
Defined as residual stenosis ≤30% immediately after completion of additional unplanned endovascular intervention(s) (any endovascular procedure that was not part of the primary procedure plan). |
Immediately after procedure completion
|
|
Need for unplanned bailout stenting
Periodo de tiempo: Immediately after procedure completion
|
Defined as any stent placement that was not part of the primary procedure plan. |
Immediately after procedure completion
|
|
Number of participants free from Clinically-Driven Target Lesion Revascularization (CD-TLR)
Periodo de tiempo: 12 and 24 months
|
Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
12 and 24 months
|
|
CD-TLR-free survival
Periodo de tiempo: Until the end of the follow-up period of 2 years
|
Defined as time between first OA procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
Until the end of the follow-up period of 2 years
|
|
Clinical response using Rutherford classification categories
Periodo de tiempo: 12 and 24 months
|
The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss. |
12 and 24 months
|
|
Wound status
Periodo de tiempo: 12 and 24 months
|
Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening). |
12 and 24 months
|
|
Freedom from amputation of the target limb
Periodo de tiempo: 12 and 24 months
|
Defined as absence of any amputation of the target limb (above ankle). |
12 and 24 months
|
|
Amputation-free survival
Periodo de tiempo: Until the end of the follow-up period of 2 years
|
Defined as time between first OA procedure and above-ankle amputation of the target limb. |
Until the end of the follow-up period of 2 years
|
|
Overall survival
Periodo de tiempo: Until the end of the follow-up period of 2 years
|
Defined as the time between the first OA procedure and death of any cause. |
Until the end of the follow-up period of 2 years
|
|
Patient-reported health-related quality-of-life
Periodo de tiempo: Baseline, 6, 12 and 24 months post treatment
|
Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD. |
Baseline, 6, 12 and 24 months post treatment
|
|
Frequency and severity of procedural complications and other adverse events
Periodo de tiempo: Within 30 days after the OA procedure
|
Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe. |
Within 30 days after the OA procedure
|
|
Clinical response using ankle-brachial index (ABI)
Periodo de tiempo: 12 and 24 months
|
The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease. |
12 and 24 months
|
|
Clinical response using toe pressure
Periodo de tiempo: 12 and 24 months
|
The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion. |
12 and 24 months
|
|
Clinical response using WIfi (wound, ischemia and foot infection) score
Periodo de tiempo: 12 and 24 months
|
The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization. |
12 and 24 months
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Silla de estudio: Gerd Grözinger, Prof. Dr. med., SLK Kliniken Heilbronn GmbH
- Silla de estudio: Marianne Brodmann, Univ.-Prof. Dr. med., Medizinische Universität Graz
- Silla de estudio: Stefan Müller-Hülsbeck, Prof. Dr. med., DIAKO Krankenhaus gGmBH
- Silla de estudio: Raghu Lakshminarayan, Dr, Hull University Teaching Hospitals NHS Trust
Publicaciones y enlaces útiles
Publicaciones Generales
- Nordanstig J, Wann-Hansson C, Karlsson J, Lundstrom M, Pettersson M, Morgan MB. Vascular Quality of Life Questionnaire-6 facilitates health-related quality of life assessment in peripheral arterial disease. J Vasc Surg. 2014 Mar;59(3):700-7. doi: 10.1016/j.jvs.2013.08.099. Epub 2013 Dec 15.
- Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification System. Cardiovasc Intervent Radiol. 2017 Aug;40(8):1141-1146. doi: 10.1007/s00270-017-1703-4. Epub 2017 Jun 5.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Enfermedad arterial periférica
- OA
- CLTI
- Isquemia crónica de extremidades
- Arterias infrapoplíteas
- Estudio observacional de cohortes
- Aterectomía orbitaria
- Preparación de buques
- Lesiones arteriales periféricas calcificadas
- Isquemia crítica de las extremidades
- Arterias femoropoplíteas
- Aterectomía para lesiones calcificadas
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Aterosclerosis
- Arteriosclerosis
- Enfermedades arteriales oclusivas
- Enfermedades vasculares periféricas
- Isquemia
- Condiciones Patológicas, Signos y Síntomas
- Isquemia crónica que amenaza las extremidades
- Enfermedad arterial periférica
Otros números de identificación del estudio
- ORACLE
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .